Improved Coagulation After Cardiopulmonary Bypass Using the Hemobag ® Scott R. Beckmann, B.S.,C.C.P. Thomas Winkler, M.D., William Shely, M.D., Salem Hospital,

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

What is Patient Blood Management?
An Essential Tool for Optimizing Clinical Outcomes and Improving Patient Safety: The Administrative and Clinical Standards for Patient Blood Management.
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
Part 2 Terry Kotrla, MS, MT(ASCP)BB
A Clinical Evaluation of Terumo’s Prescriptive Oxygenation™ Series Capiox® FX15 and FX25 Hollow Fiber oxygenators with Integrated Arterial Filter in the.
Blood Bag Coagulation & Preservers Citrate 24 hours 1-6 ºC Heparin 48 hours 1-6 ºC ACD or CPD 21 days 1-6 ºC CPD-A135 days 1-6 ºC CPD-A1+ additive.
Transfusion in Cardiopulmonary Bypass. Blood Use & Cardiac Surgery 1971 – average 8 units RBC per case Late 1980’s – Texas Heart Institute 1.4 units per.
Plasma free hemoglobin and perfusion – some things to consider Mark Yazer, MD Associate Professor of Pathology, University of Pittsburgh The Institute.
1 How we Managed to change Blood Usage with Q.I. Charles B. Yarnall Bs, CCP, LP Clinical Manager National Clinical Specialist.
Pablo M. Bedano M.D. Community Regional Cancer Care.
Blood Components Dosage And Their Administration
Intra operative blood conservation
Vigneshwar Kasirajan, M.D. Division of Cardiothoracic Surgery Vigneshwar Kasirajan, M.D. Division of Cardiothoracic Surgery.
Introduction of « TRIMA » in a Regional Blood Transfusion Organisation Dr Bernard LAMY.
BLOOD BANKING 1- BLOOD PRODUCTS 2- AUTOLOGOUS TRANSFUSION M. H. Shaheen Maadi Armed Forces Hospital.
Transfusing tiny soldiers Ramsey C. Tate, MD. Applying combat-derived massive transfusion protocols to pediatric trauma patients.
Definition of Massive Transfusion Replacement of a blood volume equivalent within 24hr Transfusion>10 unit within 24 hr Transfusion > 4 units in 1 hr.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
بسم الله الرحمن الرحيم. Ahmad Shihada Silmi,Msc, FIBMS Lecturer of Haematology & Immunology Faculty of Science, IUG Autologous Blood BY.
4th year medical students Blood Component Therapy Salwa I Hindawi MSc FRCPath CTM Director of Blood Transfusion Services KAUH. Jeddah.
A bleeding diathesis has been recognized in pt. with CCHD, a variety of coagulation abnormalities has been postulated: 1- Polycythemia 2- Hyper viscosity.
BLOOD TRANSFUSION Begashaw M (MD).
Senior clinician Request: a o 4 units RBC o 2 units FFP Consider: a o 1 adult therapeutic dose platelets o tranexamic acid in trauma patients Include:
Omar Alsuhaibani Transfusion Medicine Journal Club February 2, 2010.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
1 Quality Control Procedures During Autotransfusion AmSECT New Advances in Blood Management Meeting Seattle, Washington September 8, 2011John Rivera.
© Copyright, The Joint Commission Tracer Methodology Stacy Olea, MBA, MT(ASCP), FACHE Field Director use these colors.
Fluids and blood products in trauma
CRYOPRECIPITATE USE IN 25 CANADIAN HOSPITALS: COMMONLY USED OUTSIDE OF THE PUBLISHED GUIDELINES Edward C Alport, Jeannie L Callum, Susan Nahirniak, Bernie.
BLOOD TRANSFUSION NUR 317. TRANSFUSION Infusion of blood products for the purpose of restoring circulating volume.
Global Blood Resources LLC
Basic Clinician Training Module 4 Special circumstances: Distinguishing between different causes of bleeding.
Evaluation of CardioPAT R autotransfusion system in elective cardiac surgery. De Decker K. 1 ; Bogaert T 2* ; Gooris T 2* ; Stockman B 2 ; 1: Dept of Anesthesiology.
Blood component therapy This is the seperation of whole blood into its individual components to optimize individual therapeutic potency based on sound.
BLOOD TRANSFUSION Ms.SARITHA MOHAN B.Sc.(N) Nursing Eductor Al-Ahsa Hospital Kingdom of Saudi Arabia.
Time for an Obituary? Whole blood an entity or not? Dr. Sudipta Sekhar Das MD (Transfusion Medicine), SGPGIMS PDCC (Aphaeresis & Component Therapy), SGPGIMS.
A New Technology for Blood Conservation using Hemoconcentration A Universal Blood Reservoir for Salvaging Autologous Whole Blood from any ECC. The Hemobag.
Preparation of blood components
A Method to Reduce Allogeneic Blood Exposure after CPB: New Technology Case Series - The Hemobag ® Keith A. Samolyk CCP, LCP, Global Blood Resources LLC,
Challenges in RBC Blood Transfusion in an Academic Medical Center Dr. Kendal Williams MD, MPH Assistant Professor of Clinical Medicine Co-Director of the.
Blood Transfusion Safe Practice.
The Hemobag®a Novel Whole Blood Salvaging The Hemobag® a Novel Whole Blood Salvaging Technique and Device for Salvaging Blood from ECC’s Clinical Validation.
Platelet Transfusions Indications, dose and administration
Patient Blood Management Guidelines: Module 6 Neonatal and Paediatrics Roles Senior clinician Coordinate team and allocate roles Determine volume and type.
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
Patient Blood Management: Acute Normovolemic Hemodilution
Lako S, Daka A, Nurka T, Dedej T, Ostreni V
K A U H Blood bank Wesaam Al-Sheyyab.
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Audit of Blood Product Use in Paediatric Cardiac Bypass Surgery.
Warfarin Toxicity Treatment & Management
No:18 Red Cell Contamination In Leukapheresis Product-
Gethin Boyle St Thomas’ Hospital
Benefits of apheresis collection
Benefits of autotransfusion
Blood Utilization Program
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
Intraoperative Cell Salvage
Autologous Platelet-Rich Plasma Reduces Transfusions During Ascending Aortic Arch Repair: A Prospective, Randomized, Controlled Trial  Shao Feng Zhou,
Intraoperative Cell Salvage
What is Patient Blood Management?
Effect of Heparin Loading During Congenital Heart Operation on Thrombin Generation and Blood Loss  Sophronia O Turner-Gomes, MB, ChB, Evan P Nitschmann,
Zoe K. McQuilten, MBBS, Nick Andrianopoulos, MBBS, MBiostat, Erica M
Individualized heparin and protamine management in infants and children undergoing cardiac operations  Massimiliano Codispoti, MD, Christopher A Ludlam,
Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair  Greg Stratmann, MD, PhD, Isobel A Russell,
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis 
Minimizing blood transfusions during abdominal aortic surgery: Recent advances in rapid autotrnsfusion  J.W. Hallett, M.D., Mark Popovsky, M.D., Duane.
Blood Components Dosage And Their Administration
Presentation transcript:

Improved Coagulation After Cardiopulmonary Bypass Using the Hemobag ® Scott R. Beckmann, B.S.,C.C.P. Thomas Winkler, M.D., William Shely, M.D., Salem Hospital, Salem, OR, USA There are increasing international stresses within healthcare regarding the allogeneic blood supply, its use and associated costs and morbidity (1). The concern is arguably one of greatest in the cardiac surgery arena today (2). Improved blood administration practices have been encouraged by multiple professional societies whose members provide cardiac surgical care. (3-4). There are vast differences in transfusion practices between cardiac surgical facilities throughout the world (5). As well, there are numerous blood conservation maneuvers that are employed during cardiac surgery that have not been widely adopted as standard of care (6-8). Patient data from an underutilized ultrafiltration technique (the Hemobag ® ) to process residual extracorporeal circuit blood is presented as an example of a means to reduce allogeneic blood related risks and costs (9). This technology allows for the infusion of shed / residual blood without creating disturbances in hemodynamic or biochemical parameters, and avoidance of clinical complications or any increase in morbity (9-10, 16-17). Further studies indicate that in over 50% of patients, FFP transfusion does not reliably reduce the PT or INR and exposes patients to unnecessary risk (18-19). A prospective, evenly matched two-cohort case series design was constructed. Hematocrit, platelet count, fibrinogen concentration ([Fib]), PT, PTT and INR values were compared in 10 Hemobag ® (HB) and 10 non-HB (NHB) adult cardiac surgical patients at two times after CPB: 1) post acute normovolemic hemodilution (ANH) infusion and protamine administration, and 2) after admission to the ICU approximately one hour after CPB and HB infusion. An ANH volume (about 4 cc/kg) was withdrawn from each patient after heparinization, sequestered and returned immediately after protamine administration in both the HB and non-HB patients. Cell processing (Cell Saver ® 5; Haemonetics Corporation, Braintree MA) was also employed in both groups of patients to conserve blood. Immediately post-bypass, the residual CPB circuit blood was processed by the Cell Saver ® 5 in the NHB patients and the Hemobag ® technique was utilized in the HB patients (Figure 1). Residual heparin in the HB contents was neutralized with an additional 50mg of protamine sulfate after infusion. The decision to transfuse allogeneic blood bank products was made by the same physicians using the same transfusion criteria for both groups of patients during the time periods in this study. Process indicators and central hospital laboratory results were statistically compared by independent group t-test or ANOVA between the NHB and HB patients before and after the first hours immediately after protamine administration and the reinfusion of ATS, ANH and HB blood. Specific factor comparisons were made employing Bonferroni adjustments. The alpha level was set at 0.05 or 0.10 depending on the factors. Statistical analysis was performed using SPSS software (SPSS 14.0, Chicago, IL). Table 1 lists the patient-by-patient allogeneic, ANH, ATS and Hemobag ® volumes used in the few hours immediately post- protamine sulfate infusion. Figure 2 shows the difference between CPB and HB blood parameters. Table 2 presents the results of the statistical analysis of the differences between groups. Except for PTT, all parameters changed significantly from the post-protamine and HB, ATS and ANH blood infusion to approximately one hour after and arrival in the ICU. Figure 3 reports the cost savings by employing the Hemobag®. Fibrinogen and Hct (Figure 4) were significantly higher in the HB group at the end of the first ICU hour. Significant reductions in PT and INR were also observed after HB content infusion however, there was only a strong trend in decreased average PTT. NHB patients required significantly more donor blood products than the HB patients where nine of the ten patients required no allogeneic blood during their hospital stay. The Hemobag ® Blood Salvage Device is a reservoir system that allows the patient’s own whole blood to be salvaged, quickly hemoconcentrated and safely infused. It efficiently uses the same convenient reservoir bag while insuring CPB circuit integrity for reinstituting bypass safely and securely, if necessary. Table 1 Method Results Discussion Introduction Group PatientPlt PkgRBCFFPCryoANHHB VolATSDnr Exp Non- Hemobag ® Patients Hemobag ® Patients Note: The number of platelet packs (Plt Pkg), units of red blood cells (RBC), fresh frozen plasma (FFP) and cryoprecipitate (Cryo) transfused in the first hours after protamine infusion. ANH is acute normovolemic hemodilution and ATS is autotransfusion washed RBCs. Donor exposures (Dnr Exp) are the total number of allogeneic donor exposures observed. Table 2 ParameterTreat Post CPB In ICU ICU p HB p Event p Interact p HctNon-HB24.7 +/ / < HB24.3 +/ /- 2.3 Dnr ExpNon-HB*2.7 +/- 7.4*0.107** HB*0.8 +/- 2.5 RBCsNon-HB*1.3 +/- 2.0*0.07** HB*0 PltNon-HB*1.7 +/- 3.1*0.169** HB*0.2 +/- 0.6 FFPNon-HB*1.7 +/- 2.5*0.159** HB*0.4 +/- 1.3 CryoNon-HB*1.0 +/- 3.2*NS* HB*0.2 +/- 0.6 ATSNon-HB*1039 +/- 613*0.001** HB*248 +/- 166 INRNon-HB1.6 +/ /- 0.1NS 0.021NS HB1.6 +/ /- 0.1 PTNon-HB19.2 +/ /- 1.4NS 0.002NS HB20.6 +/ /- 1.7 PTTNon-HB35 +/ /- 4NS HB38 +/ /- 7 [Fib]Non-HB195 +/ / NS HB199 +/ /- 63 Plt CntNon-HB90 +/ /- 24NS 0.001NS HB82 +/ /- 40 Note: Values are mean +/- one standard deviation. Hemobag ® effect is between the Hemobag ® (HB) and non-HB groups. ICU is between HB and NHB in the ICU. Event is between post CPB and post one hour. Hemobag ® and allogeneic blood use Figure 4 Fibrinogen Pre and & Post Hemobag ® Infusion Hct% Pre and & Post HB Infusion INR Changes Pre and & Post HB & Blood Product Infusion Savings of Unused Blood Products In the Hemobag ® Group Figure 2 Figure 1 Preserving blood components Figure 3 ** References available on handout copy of poster. QUICK VOLUME LINE FOR ANESTHESIA OR TO THE FIELD (if necessary) 7 NHB pts. received blood products [FFP, Plt, Cryo, RBC] 1 HB pt. received blood products [FFP, Plt, Cryo,] p = NS p = < HB: p = p = < NS HB: p = p = NS All blood products for the Hemobag ® patients’ charges $1,722 vs. $12,563 for the control patients. A difference of: $10,841 Patient charges ϰ 2 (1, N=20) = 6.11, p < patients 1 patient Post-Protamine Post-Infusion Most allogeneic blood products are transfused in the first few perioperative hours and often based upon arbitrary clinical observations without adequate documentation of the need for blood bank components (3). The results of this case series strongly suggest that cardiac surgery patients may be spared donor exposures when the residual bypass circuit blood is highly concentrated and quickly reinfused as compared to cell washing (9-10). Use of the Hemobag ® for salvaging blood is associated with significant increases in the patient’s protein and cellular concentrations, that would have normally been discarded (average of costs of lost proteins +/- 4,000USD) (15) thus lowering coagulation times in the important, first few hours following CPB (11-14). Use of “multi-pass” ultrafiltration (UF) to process the residual perfusion circuit blood far exceeds the results of “single-pass” ultrafiltration methods. This technique has improved our blood administration practices and helped avoid many unnecessary transfusions. The Hemobag ® patients obtained significantly improved coagulation parameters with far fewer blood products than were required in the non-HB patients. The Hemobag ® provides patients with improved quality of care through the reduction of allogeneic blood products. Frequently, transfusions are directly related to costly, negative, patient outcomes and in many cases can be avoided (20). The Hemobag ® now offers perfusionists a new role in optimizing homeostasis & coagulation in the first few critical hours after the termination of cardiopulmonary bypass. Post-Protamine Post-Infusion